Compounders Research Compare

Prime Medicine, Inc.(PRME)

Biotechnology · Cambridge, MA

$3.50+0.29 (+9.03%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Prime Medicine, Inc.

Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.

Cambridge, MA

146 employees

www.primemedicine.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Allan Reine

View full financials

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T22:38:22.762Z.

Stored calculation inputs

Calculation as of: 2026-10-06T22:38:22.762Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 632,161,075
Total debt · period ending 2026-06-30: 112,478,000
Cash · period ending 2026-06-30: 47,451,000
TTM free cash flow · period ending 2026-06-30: -156,848,000

FMP input reference: ed0d84ebe65fc765338e7baf7154c4548c52c7814b601df66b93f049f622236d

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

PRME EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

PRME Competitors' EV/FCF Ratio

Prime Medicine, Inc.

Current

Market Cap

$632.16M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OmniAb, Inc.

Market Cap

$630.63M

EV/FCF Ratio

N/A

TTM Avg

710.97x

3Y Avg

756.83x

5Y Avg

756.83x

Zevra Therapeutics, Inc.

Market Cap

$634.30M

EV/FCF Ratio

15.06x

TTM Avg

38.21x

3Y Avg

38.21x

5Y Avg

21.28x

Aura Biosciences, Inc.

Market Cap

$638.20M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SOPHiA GENETICS S.A.

Market Cap

$619.15M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Climb Bio, Inc.

Market Cap

$611.57M

EV/FCF Ratio

N/A

TTM Avg

370.81x

3Y Avg

370.81x

5Y Avg

370.81x

4D Molecular Therapeutics, Inc.

Market Cap

$656.59M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Starling Oncology, Inc.

Market Cap

$657.89M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Annexon, Inc.

Market Cap

$660.29M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Ironwood Pharmaceuticals, Inc.

Market Cap

$597.55M

EV/FCF Ratio

4.93x

TTM Avg

12.45x

3Y Avg

11.11x

5Y Avg

9.59x

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Prime Medicine, Inc. (PRME)	$632.16M	N/A	N/A	N/A	N/A
OmniAb, Inc. (OABI)vs ›	$630.63M	N/A	710.97x	756.83x	756.83x
Zevra Therapeutics, Inc. (ZVRA)vs ›	$634.30M	15.06x	38.21x	38.21x	21.28x
Aura Biosciences, Inc. (AURA)vs ›	$638.20M	N/A	N/A	N/A	N/A
SOPHiA GENETICS S.A. (SOPH)vs ›	$619.15M	N/A	N/A	N/A	N/A
Climb Bio, Inc. (CLYM)vs ›	$611.57M	N/A	370.81x	370.81x	370.81x
4D Molecular Therapeutics, Inc. (FDMT)vs ›	$656.59M	N/A	N/A	N/A	N/A
Starling Oncology, Inc. (STLN)vs ›	$657.89M	N/A	N/A	N/A	N/A
Annexon, Inc. (ANNX)vs ›	$660.29M	N/A	N/A	N/A	N/A
Ironwood Pharmaceuticals, Inc. (IRWD)vs ›	$597.55M	4.93x	12.45x	11.11x	9.59x

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

Free Cash Flow FCF Yield P/FCF Ratio EV/EBITDA All Metrics